Allergy Therapeutics plc (LON:AGY) insider Tunde Otulana bought 25,000 shares of the business’s stock in a transaction dated Wednesday, October 11th. The shares were bought at an average cost of GBX 51 ($0.67) per share, for a total transaction of £12,750 ($16,763.08).

Allergy Therapeutics plc (AGY) traded down 0.66% during trading on Thursday, hitting GBX 37.75. The stock had a trading volume of 101,757 shares. Allergy Therapeutics plc has a 12 month low of GBX 19.50 and a 12 month high of GBX 39.50. The company’s market cap is GBX 224.28 million. The company’s 50 day moving average is GBX 31.85 and its 200-day moving average is GBX 28.57.

TRADEMARK VIOLATION NOTICE: “Allergy Therapeutics plc (AGY) Insider Acquires £12,750 in Stock” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at

Several research firms have recently weighed in on AGY. FinnCap boosted their target price on Allergy Therapeutics plc from GBX 43 ($0.57) to GBX 46 ($0.60) and gave the company a “buy” rating in a research report on Tuesday, July 18th. Panmure Gordon reissued a “buy” rating on shares of Allergy Therapeutics plc in a research report on Thursday, September 28th. Finally, Numis Securities Ltd reissued a “buy” rating and set a GBX 45 ($0.59) target price on shares of Allergy Therapeutics plc in a research report on Thursday, September 28th.

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with Analyst Ratings Network's FREE daily email newsletter.